Frazier Life Sciences, a healthcare investment firm, led a $182m Series C round in Bluejay Therapeutics, a developer of novel therapeutics, with participation from RA Capital Management, T. Rowe Price, Wellington Management, Novo Holdings, RiverVest Venture Partners, Octagon Capital, Arkin Bio Ventures, HBM Healthcare Investments and Unicorn Capital. "We are immensely grateful for the robust support from both new and returning investors, which reflects confidence in our strategy and our team’s ability to deliver on our mission. This funding not only empowers us to drive our lead assets through critical clinical trials but also enhances our capacity to address significant unmet medical needs in global health," Keting Chu, Bluejay Therapeutics Founder and CEO.